Panacea Life Sciences Holdings Capital Expenditures (CapEx) Growth & History (PLSH)
Panacea Life Sciences Holdings's capital expenditures (capex) was $65,322 for fiscal 2023.
View full Panacea Life Sciences Holdings company overviewPanacea Life Sciences Holdings annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2023 | 2023-12-31 | $65,322 | −$178,482 | −73.21% |
| 2022 | 2022-12-31 | $243,804 | $80,858 | +49.62% |
| 2021 | 2021-12-31 | $162,946 | $162,946 | — |
| 2020 | 2020-12-31 | $0 | −$541,203 | — |
| 2019 | 2019-12-31 | $541,203 | $541,203 | — |
| 2018 | 2018-12-31 | $0 | — | — |
| 2016 | 2016-12-31 | $1,292 | $1,292 | — |
| 2015 | 2015-12-31 | $0 | −$6,018 | — |
| 2014 | 2014-12-31 | $6,018 | — | — |
Panacea Life Sciences Holdings quarterly capital expenditures (capex)
| Fiscal quarter | Period ended | Capital expenditures (CapEx) | Change | YoY change |
|---|---|---|---|---|
| Q1 2024 | 2024-03-31 | $5,000 | −$10,220 | −67.15% |
| Q2 2023 | 2023-06-30 | $9,350 | $1,471 | +18.67% |
| Q1 2023 | 2023-03-31 | $15,220 | $5,495 | +56.50% |
| Q4 2022 | 2022-12-31 | $98,843 | $89,392 | +945.85% |
| Q3 2022 | 2022-09-30 | $127,357 | $113,557 | +822.88% |
| Q2 2022 | 2022-06-30 | $7,879 | −$91,549 | −92.08% |
| Q1 2022 | 2022-03-31 | $9,725 | −$77,044 | −88.79% |
| Q4 2021 | 2021-12-31 | $9,451 | −$3.3M | −99.71% |
| Q3 2021 | 2021-09-30 | $13,800 | −$3.3M | −99.58% |
| Q2 2021 | 2021-06-30 | $99,428 | $99,428 | — |
| Q1 2021 | 2021-03-31 | $86,769 | $86,769 | — |
| Q4 2020 | 2020-12-31 | $3.3M | $3.3M | +7236.73% |
| Q3 2020 | 2020-09-30 | $3.3M | $3.1M | +1544.01% |
| Q2 2020 | 2020-06-30 | $0 | −$356,882 | — |
| Q1 2020 | 2020-03-31 | $0 | −$28,500 | — |
| Q4 2019 | 2019-12-31 | $45,000 | $45,000 | — |
| Q3 2019 | 2019-09-30 | $200,821 | $200,821 | — |
| Q2 2019 | 2019-06-30 | $356,882 | $356,882 | — |
| Q1 2019 | 2019-03-31 | $28,500 | $28,500 | — |
| Q4 2018 | 2018-12-31 | $0 | — | — |
| Q3 2018 | 2018-09-30 | $0 | — | — |
| Q2 2018 | 2018-06-30 | $0 | — | — |
| Q1 2018 | 2018-03-31 | $0 | — | — |
| Q4 2016 | 2016-12-31 | $0 | $0 | — |
| Q3 2016 | 2016-09-30 | $0 | $0 | — |
| Q2 2016 | 2016-06-30 | $1,292 | −$230 | −15.11% |
| Q1 2016 | 2016-03-31 | $0 | −$1,522 | — |
| Q4 2015 | 2015-12-31 | $0 | — | — |
| Q3 2015 | 2015-09-30 | $0 | $0 | — |
| Q2 2015 | 2015-06-30 | $1,522 | — | — |
| Q1 2015 | 2015-03-31 | $1,522 | — | — |
| Q3 2014 | 2014-09-30 | $0 | — | — |
Panacea Life Sciences Holdings capital expenditures (capex) trends
Over the last five fiscal years, Panacea Life Sciences Holdings's capital expenditures (capex) increased from $0 to $65,322, a change of $65,322. The latest reported quarter, Q1 2024, shows $5,000.
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Panacea Life Sciences Holdings source filings ↗